Skip to main content

Walmart Hit With Discovery Sanctions In Opioid MDL

Walmart Hit With Discovery Sanctions In Opioid MDL

Walmart Hit With Discovery Sanctions In Opioid MDL

Introduction

Walmart is now listed as one of the defendants in the multidistrict litigation (MDL) in Ohio with allegations that Walmart’s pharmacies improperly distributed opioids fueling the nationwide epidemic.

The MDL includes more than 2,000 opioid-related claims from the state, local, and tribal governments. The special master, David Cohen, who is overseeing the MDL discovery, ordered new declarations of Walmart witnesses by sanctioning the company for insurgence with a longstanding discovery order. The order states the defendants need to provide relevant documents from other opioid cases, which are not part of the consolidated cases.

Walgreens, CVS, Walmart, and other pharmacies requested to remove the 2019 motion that included cases outside of the MDL. The companies argued that ruling from the 6th U.S. Circuit Court of Appeals in April 2020 was an overly broad request for discovery. However, in June 2020, the judge refused to withdraw the request.

Walmart provided a PowerPoint presentation to the U.S. Department of Justice (DOJ), which included documents covered under the order. The judge stated that Delaware's opioid litigation is related to Walmart's prescription policies, and shareholders are seeking for access to its records.

The judge stated that Walmart provided illogical explanations of the order to tackle the production of the documents and use it to delay or avoid complying with the court orders.

The spokesperson for Walmart said that the company is following the rules of the court and will continue to defend the litigation. However, the recently sanctioned order has only worsened the matters for the retailer in the litigation.

In October 2017, National Prescription Opiate Litigation MDL No. 2804 (In Re: National Prescription Opiate Litigation) was formed overlooked by U.S. District Judge Dan Aaron Polster.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.